Chromocell Therapeutics (CHRO) Institutional Ownership → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free CHRO Stock Alerts $1.82 +0.07 (+4.00%) (As of 05/20/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsSocial Media Institutional Ownership Changes (13F Filings) for Chromocell Therapeutics (NYSE:CHRO)CurrentInstitutional OwnershipPercentage77.96%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$659.95KNumber ofInstitutional Sellers(last 12 months)0 Get CHRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Chromocell Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. Chromocell Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2024 Anson Funds Management LP251,888$660K0.0%N/A4.284% (Data available from 1/1/2016 forward) CHRO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CHRO shares? During the previous two years, the following institutional investors and hedge funds held shares of Chromocell Therapeutics shares: Anson Funds Management LP ($660K).Learn more on CHRO's institutional investors. What percentage of Chromocell Therapeutics stock is owned by institutional investors? 77.96% of Chromocell Therapeutics stock is owned by institutional investors. Learn more on CHRO's institutional investor holdings. Which institutional investors have been buying Chromocell Therapeutics stock? The following institutional investors have purchased Chromocell Therapeutics stock in the last 24 months: Anson Funds Management LP ($251.89K). How much institutional buying is happening at Chromocell Therapeutics? Institutional investors have bought a total of 251,888 shares in the last 24 months. This purchase volume represents approximately $659.95K in transactions. Related Companies: Genetic Technologies Institutional Ownership BioCardia Institutional Ownership Inhibikase Therapeutics Institutional Ownership Coeptis Therapeutics Institutional Ownership Creative Medical Technology Institutional Ownership Tevogen Bio Institutional Ownership Senti Biosciences Institutional Ownership Finch Therapeutics Group Institutional Ownership PharmaCyte Biotech Institutional Ownership Aptose Biosciences Institutional Ownership This page (NYSE:CHRO) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyThe #1 Crypto for AIWeiss RatingsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
